Novartis Third quarter 2012 results
Novartis Third quarter 2012 results
Recently launched products support Novartis sales in third quarter, offsetting
patent expiry; Pharmaceuticals well-positioned with further pipeline progress
Group net sales declined 2% in constant currencies (cc) in the third quarter, down 1% over
nine months
o Third quarter net sales reached USD 13.8 billion (-7%, -2% cc); nine months net sales were USD
41.8 billion (-4%, -1% cc)
o Core1 operating income was USD 3.9 billion (-5%, -3% cc) in third quarter, USD 11.5 billion
(-7%, -4% cc) in nine months; operating income reached USD 3.0 billion (+3%, +5% cc) in the
third quarter and USD 9.0 billion (-7%, -4% cc) for the nine months
o Core EPS was USD 1.34 (-8%, -6% cc) in third quarter, USD 3.98 (-8%, -5% cc) in nine months;
EPS was USD 1.01 (-1%, +2% cc) in third quarter and USD 3.09 (-7%, -4% cc) in nine months
o Free cash flow1 reached USD 3.5 billion for third quarter (2011 USD 3.7 billion); USD 7.9 billion
in nine months (2011 USD 8.6 billion)
Strong flow of innovation news continues; respiratory portfolio prospects significantly
advanced with QVA149 EU filing
o Eight regulatory milestones in Pharmaceuticals, including Afinitor FDA and EMA approval in
advanced breast cancer, Jakavi EMA approval in myelofibrosis and Seebri Breezhaler EMA
approval in COPD
o Respiratory portfolio progressed with strong Phase III trials of QVA149 leading to filing in the EU
Recently launched products in Pharmaceuticals totaled USD 2.8 billion and represented 36%
of net sales (USD 8.3 billion and 35% of net sales for nine months); Pharmaceuticals wellpositioned
to emerge from Diovan patent expiry
Quality remediation continues to be actively addressed; first Consumer Health products
resupplied in the US from third party sources
2012 Group performance outlook reaffirmed
Key figures
novartis
Novartis Q3 and 9M 2012 Interim Financial Report – Supplementary Data
novartis
URLs at talkstock